Mark Leonard Singleton Sells 6,498 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 6,498 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the completion of the transaction, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at approximately $1,210,745.23. This trade represents a 5.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The shares were sold at an average price of $10.53, for a total value of $113,018.49.

Bioventus Price Performance

Shares of BVS stock traded down $0.37 during trading hours on Thursday, reaching $9.95. The company had a trading volume of 322,403 shares, compared to its average volume of 272,552. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The stock has a fifty day moving average of $10.37 and a 200-day moving average of $10.83. The company has a market capitalization of $807.44 million, a price-to-earnings ratio of -16.31 and a beta of 0.85. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38.

Analyst Ratings Changes

BVS has been the subject of a number of analyst reports. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and upped their price target for the stock from $12.00 to $13.00 in a report on Tuesday, December 17th. Canaccord Genuity Group boosted their price objective on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

Institutional Investors Weigh In On Bioventus

A number of large investors have recently made changes to their positions in BVS. Royce & Associates LP purchased a new stake in shares of Bioventus in the third quarter valued at approximately $8,337,000. Vanguard Group Inc. grew its position in shares of Bioventus by 18.7% in the fourth quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock valued at $25,852,000 after purchasing an additional 388,174 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Bioventus in the third quarter valued at approximately $4,515,000. Driehaus Capital Management LLC grew its position in shares of Bioventus by 33.7% in the fourth quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company’s stock valued at $11,758,000 after purchasing an additional 282,341 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Bioventus in the third quarter valued at approximately $3,092,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.